Close Menu


Researchers used whole-genome shotgun metagenomic sequencing to home in on specific bacteria associated with patients' response to immune checkpoint inhibitor treatment.

The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.

Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.

The collaboration will test the effects of using human microbiome-derived bacteria alongside immune checkpoint inhibitor nivolumab to treat advanced metastatic cancers.

Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.